NCT07145814COMPLETEDanonymous

Dexmedetomidine Dose-Dependent Modulation of Lung Function and AQP1 Expression During One-Lung Ventilation in Adults Undergoing Thoracoscopic Surgery: A Randomized Controlled Trial

Sponsor

Source record

People's Hospital of Guangxi Zhuang Autonomous Region

Phase

Source record

Modality

AI-normalized

small molecule

Target

AI-normalized

dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline

Indication / condition

AI-normalized

Acute Lung Injury(ALI)

Intervention

Source record

dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline

Source & freshness

Source record

NCT ID

NCT07145814

Original source

ClinicalTrials.gov

Source last updated

Aug 28, 2025

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07145814

Title

Dexmedetomidine Dose-Dependent Modulation of Lung Function and AQP1 Expression During One-Lung Ventilation in Adults Undergoing Thoracoscopic Surgery: A Randomized Controlled Trial

Sponsor

People's Hospital of Guangxi Zhuang Autonomous Region

Status

COMPLETED

Phase

Condition raw

Acute Lung Injury(ALI)

Condition normalized

Acute Lung Injury(ALI)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline

Target normalized

dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline

Interventions

dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline

Public preview

Source record

This randomized controlled trial evaluated the dose-dependent effects of dexmedetomidine (DEX) on pulmonary function and aquaporin-1 (AQP1) expression during one-lung ventilation (OLV) in thoracoscopic surgery.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Dexmedetomidine Dose-Dependent Modulation of Lung Function and AQP1 Expression During One-Lung Ventilation in Adults Undergoing Thoracoscopic Surgery: A Randomized Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07145814

Status

COMPLETED

Phase

Sponsor

People's Hospital of Guangxi Zhuang Autonomous Region

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 28, 2025

Internal syncMay 23, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07145814

Indication

Acute Lung Injury(ALI)

Modality

small molecule

Target

dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline

Intervention

dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.